Lantern Pharma Inc. Research and Development in Process
Lantern Pharma Inc. (LTRN) reported Research and Development in Process of $2.24 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-10.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentInProcess · last filed 2021-03-10
- Lantern Pharma Inc. research and development in process for the quarter ending 2020-12-31 was $1.35M, a 659.76% increase year-over-year.
- Lantern Pharma Inc. research and development in process for the quarter ending 2020-09-30 was $600.77K, a 163.03% increase year-over-year.
- Lantern Pharma Inc. research and development in process for the quarter ending 2020-06-30 was $157.02K, a 56.54% decline year-over-year.
- Lantern Pharma Inc. research and development in process for the quarter ending 2020-03-31 was $137.10K.
- Lantern Pharma Inc. research and development in process for fiscal 2020 was $2.24M, a 135.34% increase from fiscal 2019.
- Lantern Pharma Inc. research and development in process for fiscal 2019 was $953.18K.
| Period end | Research and Development in Process 3 month | Research and Development in Process 6 month | Research and Development in Process 9 month | Research and Development in Process 12 month |
|---|---|---|---|---|
| 2020-12-31 | $1.35M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-10 | $1.95M derived: sum of 2 quarters · filed 2021-03-10 | $2.11M derived: sum of 3 quarters · filed 2021-03-10 | $2.24M 10-K · filed 2021-03-10 |
| 2020-09-30 | $600.77K 10-Q · filed 2020-10-29 | $757.79K derived: sum of 2 quarters · filed 2020-10-29 | $894.90K 10-Q · filed 2020-10-29 | $1.07M derived: sum of 4 quarters · filed 2021-03-10 |
| 2020-06-30 | $157.02K 10-Q · filed 2020-07-30 | $294.13K 10-Q · filed 2020-07-30 | $471.59K derived: sum of 3 quarters · filed 2021-03-10 | $700.00K derived: sum of 4 quarters · filed 2021-03-10 |
| 2020-03-31 | $137.10K derived: 10-K 12 month − 3 quarters · filed 2021-03-10 | $314.57K derived: sum of 2 quarters · filed 2021-03-10 | $542.97K derived: sum of 3 quarters · filed 2021-03-10 | $904.25K derived: sum of 4 quarters · filed 2021-03-10 |
| 2019-12-31 | $177.47K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-10 | $405.87K derived: sum of 2 quarters · filed 2021-03-10 | $767.14K derived: sum of 3 quarters · filed 2021-03-10 | $953.18K 10-K · filed 2021-03-10 |
| 2019-09-30 | $228.40K 10-Q · filed 2020-10-29 | $589.67K derived: sum of 2 quarters · filed 2020-10-29 | $775.72K 10-Q · filed 2020-10-29 | |
| 2019-06-30 | $361.27K 10-Q · filed 2020-07-30 | $547.32K 10-Q · filed 2020-07-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |